Active Ingredient History

  • Now
Revefenacin (trade name Yupelri is a long-acting muscarinic antagonist developed by Mylan Ireland ltd for the treatment of chronic obstructive pulmonary disease (COPD). It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo models, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours.   NCATS

  • SMILES: CN(CCN1CCC(CC1)OC(=O)Nc2ccccc2c3ccccc3)C(=O)c4ccc(CN5CCC(CC5)C(=O)N)cc4
  • Mol. Mass: 597.76
  • ALogP: 4.84
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$25.2330 - $36.0705
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

biphenyl-2-ylcarbamic acid 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester | gsk1160724 | revefenacin | td-4208


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue